DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Semaglutide reduces alcohol craving and intake in early trials. Patients on GLP‑1s frequently report spontaneous reductions in drinking that match the mechanism.
Two randomized trials, and the headline number misleads. In a 26-week Lancet trial, 108 treatment-seeking adults with moderate-to-severe AUD plus obesity took semaglutide 2.4 mg or placebo, both alongside cognitive behavioural therapy: heavy-drinking days fell 41.1 percentage points on semaglutide — but also 26.4 points on placebo, because everyone got the therapy. The drug's own contribution is the 13.7-point difference (p=0.0015). An earlier phase 2 trial (Hendershot, JAMA Psychiatry 2025) pointed the same way in 48 people at lower doses.
Addiction-medicine specialists and academic centres; further trials ongoing. Some clinicians prescribe off-label for refractory AUD when standard therapy has failed.
Not first-line, and the trial evidence is explicitly an ADD-ON to therapy, not a replacement for it. Naltrexone, acamprosate, and counselling remain standard of care. No GLP-1 is FDA-approved for AUD. Coordinate with addiction medicine; insurance approval is rare.
The best-evidenced off-label use — but read the effect size honestly: about a third of the headline, on top of therapy. If you have AUD plus obesity, that is a genuine reason to discuss a GLP-1. If AUD alone, the case is much weaker.
Editorial summary. Off-label use is legal but not FDA-evaluated. Insurance typically does not cover off-label prescriptions. Not medical advice.